MREO
Mereo BioPharma GroupCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The post-earnings company update kept three forward hooks alive: setrusumab regulatory discussions are underway, alvelestat partnering remains active, and cash guidance into mid-2027 was reaffirmed. With a market cap near reported cash, even modest external validation on setrusumab or alvelestat could move the shares materially.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Alvelestat Phase 3 timing appears dependent on securing a partner, so delay or weak deal terms would prolong the value gap.
Momentum
91
Value
42
Sentiment
24
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.24 · Bull $0.45 · Bear $0.12
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-28 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $3.44
Why
Momentum91 · Δ7d -
Value42 · Δ7d -17.5
Sentiment24 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
91
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
42
32% active weight
Current posture
7d trendSoftening
Δ7d
-17.5
Δ21d
-17.3
Sentiment
24
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 91.0 / Value 41.9 / Sentiment 23.9
Fundamentals (TTM)As of 2026-05-28
Fundamentals (TTM)
As of 2026-05-28
Market Cap
$55.07M
Beta
0.31
Shares Out
795.48M
P/E (TTM) · Derived
-0.2
P/S (TTM)
152.96
P/FCF (TTM) · Derived
-0.33
Rev YoY
-
EPS YoY
+54.9%
Gross Margin
+73.6%
Op Margin
-9398.2%
Net Debt
-$64.27M
Current Ratio
8.71
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology

